6-{3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-6H-pyridazin-1-yl]-propionylamino}-nicotinic acid methyl ester | 1191452-39-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-{3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-6H-pyridazin-1-yl]-propionylamino}-nicotinic acid methyl ester
• 英文别名: methyl 6-[[3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydronaphthalen-1-yloxy)pyridazin-1-yl]propanoyl]amino]pyridine-3-carboxylate
• CAS: 1191452-39-7
• 化学式: C₂₉H₃₂N₄O₅
• 分子量: 516.597
• InChiKey: USTFTUKTAWRDFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-6H-pyridazin-1-yl]-propionic acid 、 6-氨基烟酸甲酯 以afforded 6-{3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-6H-pyridazin-1-yl]-propionylamino}-nicotinic acid methyl ester as an off-white solid (153 mg, 38%)的产率得到6-{3-cyclopentyl-2-[6-oxo-4-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-6H-pyridazin-1-yl]-propionylamino}-nicotinic acid methyl ester
  参考文献：
  名称：

  PYRIDAZINONE GLUCOKINASE ACTIVATORS

  摘要：

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范所披露。这些化合物和含有它们的药物组合物，对于治疗代谢性疾病和疾病非常有用，例如2型糖尿病。

  公开号：

  US20090264434A1

文献信息

• Pyridazinone glucokinase activators
  申请人：Hoffmann-La Roche Inc.

  公开号：US08258134B2

  公开（公告）日：2012-09-04

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  本文提供了公式（I）化合物及其药学上可接受的盐，其中取代基如规范中所述。这些化合物及含有它们的药物组合物，可用于治疗代谢性疾病和紊乱，例如2型糖尿病。
• US8258134B2
  申请人：——

  公开号：US8258134B2

  公开（公告）日：2012-09-04
• [EN] PYRIDAZINONE GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE PYRIDAZINONE GLUCOKINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009127544A1

  公开（公告）日：2009-10-22

  Provided herein are compounds of the formula (I), wherein X, Y, Q and R1 to R3 are defined in the specification, as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.